FDA Grants Orphan Drug Designation to Zamubafusp Alfa
Attralus, a clinical-stage biopharmaceutical company focused on systemic amyloidosis, has announced an important regulatory milestone. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to zamubafusp alfa (AT-02) for the treatment of immunoglobulin light-chain-associated (AL) amyloidosis.
This designation highlights the potential of zamubafusp alfa as a treatment option for a rare and serious disease that currently has limited therapeutic choices available for patients.
Understanding AL Amyloidosis
AL amyloidosis is a rare and progressive disease that occurs when abnormal proteins called amyloid deposits build up in organs and tissues throughout the body.
The disease most commonly affects the heart and kidneys, leading to serious complications and organ damage over time. If left untreated, AL amyloidosis can become life-threatening.
Globally, an estimated 74,000 people are living with AL amyloidosis. In the United States alone, around 25,000 people are affected, with approximately 4,500 new cases diagnosed each year.
The disease develops when abnormal plasma cells produce toxic light chains that form amyloid deposits in different organs. These deposits interfere with normal organ function and can significantly impact quality of life.
Why This FDA Designation Matters
The FDA's Orphan Drug Designation is intended for therapies that target rare diseases affecting fewer than 200,000 people in the United States.
Receiving this designation offers several advantages to companies developing treatments for rare conditions. These benefits may include:
For patients, the designation is often viewed as a positive sign that a promising therapy is moving forward in development.
What Is Zamubafusp Alfa?
Zamubafusp alfa is Attralus' lead therapeutic candidate and is being developed as a pan-amyloid removal treatment.
Unlike current therapies that mainly focus on reducing the production of harmful light chains, zamubafusp alfa is designed to directly target and remove existing amyloid deposits that have already accumulated in organs.
The therapy combines a humanized monoclonal antibody with Attralus' proprietary pan-amyloid binding peptide technology. This allows the treatment to recognize and bind to different forms of amyloid deposits throughout the body.
Once attached to amyloid deposits, the antibody component activates the immune system, encouraging the removal of these toxic protein accumulations.
How the Treatment Works
The unique design of zamubafusp alfa aims to address one of the biggest unmet needs in AL amyloidosis treatment.
Current approved therapies help stop the formation of new amyloid deposits by targeting abnormal plasma cells. While these treatments can slow disease progression, they do not directly remove amyloid that has already damaged organs.
Zamubafusp alfa is designed to:
Preclinical research has shown that the therapy can bind to multiple amyloid types, stimulate macrophage-mediated clearance, and reduce amyloid accumulation in major organs.
Current Clinical Development Status
Attralus has already completed a Phase 1 clinical study evaluating zamubafusp alfa.
The company is also conducting an ongoing Phase 2 open-label trial that includes patients with AL amyloidosis.
These studies are designed to evaluate the safety, tolerability, and therapeutic potential of the treatment while generating data to support future development.
Company Perspective on the Milestone
Gregory Bell, M.D., Chief Medical Officer at Attralus, emphasized the importance of developing therapies that go beyond controlling disease progression.
According to Bell, currently approved treatments primarily focus on reducing light-chain production and preventing the formation of new amyloid deposits. However, patients still face significant challenges from existing amyloid accumulation that continues to cause organ damage.
He noted that there remains a substantial need for therapies capable of removing toxic amyloid fibrils already present in the body.
Additional Global Regulatory Recognition
The FDA designation for AL amyloidosis is not the first regulatory recognition for zamubafusp alfa.
The therapy has also received:
These recognitions reflect growing interest in the therapy's potential across multiple forms of systemic amyloidosis.
The Need for Better Treatment Options
Today, the standard treatment approach for AL amyloidosis often includes a combination of therapies such as daratumumab, cyclophosphamide, bortezomib, and dexamethasone.
While these treatments help control the underlying disease, no approved therapy currently exists that directly removes amyloid deposits from affected organs.
Many patients achieve hematologic remission but continue to experience heart or kidney dysfunction caused by existing amyloid buildup.
This creates a significant treatment gap and highlights the need for therapies that can help restore organ function while improving long-term outcomes.
Looking Ahead
The FDA's Orphan Drug Designation represents another important step forward for Attralus and its lead candidate, zamubafusp alfa.
As clinical development continues, the company hopes to demonstrate that directly removing amyloid deposits can provide meaningful benefits for patients living with AL amyloidosis and other forms of systemic amyloidosis.
If successful, zamubafusp alfa could become an important addition to the treatment landscape by addressing a critical unmet need that current therapies do not fully solve.